GOTHENBURG, Sweden, Feb. 3, 2026 /PRNewswire/ --
Fourth quarter
-- Sales of SEK 891 (959) million, organic growth in local currencies
excluding discontinued business* were 6%, 3% growth in local currencies
and 7% decrease in SEK, due to a significant currency impact of -10%.
-- Sales per region, in local currencies, were -1% in EMEA excluding
discontinued business, +9% in Americas and +10% in APAC.
-- Sales per product group, in local currencies excluding discontinued
business, were +10% in Consumables, +6% in Technologies and +1% in
Genetics.
-- Gross margin decreased to 58.0% (61.1). Gross margin excluding
restructuring costs was 58.6% (61.1).
-- Earnings before depreciation and amortisation (EBITDA) amounted to SEK
196 (337) million, resulting in an EBITDA margin of 22.0% (35.1). EBITDA
excluding restructuring costs amounted to SEK 251 (337) million,
resulting in an EBITDA margin of 28.2% (35.1) impacted by negative
currency effect.
-- Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and
SEK 49 million in operating expenses.
-- An impairment charge of SEK 5,357 million was reported as other operating
expenses.
-- Net income amounted to SEK -5,314 (139) million, resulting in earnings
per share of SEK -39.24 (1.02). Net income excluding the impairment
charge and restructuring costs amounted to SEK 89 million (139),
resulting in earnings per share of SEK 0.66 (1.02).
-- Operating cash flow amounted to SEK 160 (268) million.
Full year
-- Sales of SEK 3,440 (3,609) million, organic growth in local currencies
excluding discontinued business was 4%, 2% growth in local currencies and
5% decrease in SEK, due to a significant currency impact of -6%.
-- Sales per region, in local currencies, were +5% in EMEA excluding
discontinued business, +8% in Americas and -1% in APAC.
-- Sales per product group, in local currencies excluding discontinued
business, were +8% in Consumables, +1% in Technologies and +3% in
Genetics.
-- Gross margin decreased to 58.1% (59.3). Gross margin excluding
restructuring costs was 58.2% (59.3).
-- Earnings before depreciation and amortisation (EBITDA) amounted to SEK
949 (1,225) million, resulting in an EBITDA margin of 27.6% (34.0).
EBITDA excluding restructuring costs amounted to SEK 1,004 (1,225)
million, resulting in an EBITDA margin of 29.2% (34.0) significantly
impacted by negative currency effect.
-- Restructuring costs of SEK 55 million whereof SEK 6 million in COGS and
SEK 49 million in operating expenses.
-- An impairment charge of SEK 5,357 million was reported as other operating
expenses.
-- Net income amounted to SEK -5,013 (514) million, resulting in earnings
per share of SEK -37.01 (3.78). Net income excluding the impairment
charge and restructuring costs amounted to SEK 390 million (514),
resulting in earnings per share of SEK 2.89 (3.78).
-- Operating cash flow amounted to SEK 635 (907) million.
Dividend
-- The Board to propose to the Annual General Meeting a dividend of SEK 149
(149) million, corresponding to SEK 1.10 (1.10) per share.* Discontinued
business refers to discontinued activities in certain markets in EMEA.
Gothenburg, February 3, 2026
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2026 08:00 CET.
CONTACT:
Amelie Wilson,
Investor relations,
external corporate communications and executive support,
awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/vitrolife-ab--publ-/r/fourth-quarter-and-full-year-report-2025,c4301569
The following files are available for download:
https://mb.cision.com/Main/1031/4301569/3912746.pdf Full year report 2025
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---fourth-quarter-and-full-year-report-2025-302677313.html
SOURCE Vitrolife AB (publ)
(END) Dow Jones Newswires
February 03, 2026 02:26 ET (07:26 GMT)
Comments